How Much Does Jatenzo Cost in Ohio in 2026?

Ohio Retail Pricing for Jatenzo in 2026

The average cash-pay price for Jatenzo across Ohio retail pharmacies sits at roughly $900 per month in 2026, matching the manufacturer list price set by Tolmar Pharmaceuticals. This figure applies to patients filling prescriptions without insurance or whose plans exclude the drug.

Jatenzo received FDA approval in March 2019 as the first oral testosterone undecanoate capsule indicated for testosterone replacement therapy in adult males with conditions associated with a deficiency or absence of endogenous testosterone. The key registration trial by Swerdloff et al. (2020) demonstrated that 87% of men achieved average serum testosterone concentrations within the normal range (300 to 1,100 ng/dL) at the 237 mg twice-daily dose. This oral formulation bypasses first-pass hepatic metabolism through its lymphatic absorption pathway, a pharmacokinetic advantage documented in the drug's prescribing information.

Ohio ranks among the top 10 states for TRT prescriptions per capita, according to IQVIA prescription audit data. The state's mix of large health systems (Cleveland Clinic, Ohio State Wexner Medical Center, UC Health) and independent pharmacies means pricing can vary by $50 to $150 depending on location. Patients in rural southeastern Ohio may face more limited pharmacy options, though mail-order services eliminate this gap. GoodRx and similar discount platforms occasionally list Jatenzo below $850 at select Ohio chains, but availability fluctuates.

Ohio Medicaid Coverage Status

Ohio Medicaid does not cover Jatenzo for standard male hypogonadism as of 2026. The Ohio Department of Medicaid formulary restricts oral testosterone undecanoate to narrow use cases. This means most Medicaid-enrolled men seeking TRT in Ohio are directed toward injectable testosterone cypionate or topical gels covered under the preferred drug list.

The Endocrine Society's 2018 clinical practice guideline recommends testosterone replacement for men with symptomatic hypogonadism confirmed by two morning serum testosterone measurements below 300 ng/dL. The guideline does not specify a preferred formulation, leaving room for oral, injectable, and transdermal options. Ohio Medicaid's exclusion of Jatenzo is a cost-driven formulary decision rather than a clinical one.

Men enrolled in Ohio Medicaid managed care plans (Buckeye Health Plan, CareSource, Molina, UnitedHealthcare Community Plan, Anthem, AmeriHealth Caritas) should contact their plan's pharmacy benefits line for any recent formulary updates. Prior authorization requests can sometimes succeed when documentation shows intolerance or contraindication to cheaper alternatives. A 2021 analysis in JAMA Network Open found that prior authorization denials for branded TRT formulations are overturned on appeal in approximately 30% to 40% of cases when supported by clinical documentation of adverse reactions to first-line agents.

Commercial Insurance Coverage in Ohio

Several major Ohio commercial insurers include Jatenzo on their formularies, though most place it on a specialty or non-preferred brand tier requiring prior authorization. Plans from Anthem Blue Cross Blue Shield of Ohio, Medical Mutual, SummaCare, and Aetna have been reported to cover Jatenzo with step therapy requirements. Patients typically must document failure of or intolerance to at least one injectable testosterone formulation before the plan approves oral TU.

The American Urological Association's 2018 guidelines on testosterone deficiency support treatment individualization, which strengthens appeals for oral formulations when injectable options prove impractical. Men with needle phobia, coagulopathy, or occupational constraints (truck drivers, pilots subject to FAA medical standards) may have stronger cases for oral TRT coverage.

Tier 3 or specialty tier copays in Ohio commercial plans typically range from $75 to $250 per month for Jatenzo after prior authorization approval. A Health Affairs analysis of specialty drug cost-sharing found that tiered formulary placement increases patient out-of-pocket spending by 2.5x to 4x compared to preferred brand tiers. Patients should request a formulary exception or tier reduction through their prescriber if the copay exceeds their budget.

The Tolmar Savings Card Program

Tolmar Pharmaceuticals offers a manufacturer savings card that reduces Jatenzo's out-of-pocket cost to as low as $75 per month for eligible commercially insured patients. The card covers the difference between the patient's copay and $75, up to a maximum annual benefit. Patients with government insurance (Medicare, Medicaid, Tricare, VA) are not eligible for the savings card per the Anti-Kickback Statute and OIG guidance.

Eligibility requirements for the Tolmar savings program: a valid Jatenzo prescription, commercial insurance that covers the drug (even at a high copay tier), and U.S. residency. Uninsured patients may qualify for Tolmar's separate patient assistance program, which provides Jatenzo at no cost for qualifying low-income individuals.

Ohio patients can activate the savings card at any participating retail pharmacy, including CVS, Walgreens, Kroger, and Giant Eagle Pharmacy locations. The card applies at the point of sale and does not require mail-order enrollment. The National Council for Prescription Drug Programs (NCPDP) standard pharmacy claims process handles manufacturer copay cards as secondary payers, so the transaction is straightforward for Ohio pharmacists.

Compounded Oral Testosterone Undecanoate in Ohio

Licensed 503A compounding pharmacies in Ohio can legally prepare oral testosterone undecanoate capsules as patient-specific prescriptions. This pathway is permitted under the Drug Quality and Security Act (DQSA) of 2013, which allows 503A pharmacies to compound medications based on individual prescriptions from licensed prescribers.

Compounded oral TU pricing varies but is substantially lower than branded Jatenzo. Some Ohio 503A pharmacies offer it for $100 to $300 per month depending on the dose and capsule count. The key tradeoff: compounded formulations lack the specific self-emulsifying drug delivery system (SEDDS) technology in Jatenzo that maximizes lymphatic absorption. A pharmacokinetic study published in Clinical Pharmacology & Therapeutics showed that the SEDDS formulation significantly improves testosterone undecanoate bioavailability compared to standard oil-filled capsules.

Ohio's Board of Pharmacy regulates 503A compounding facilities under Ohio Revised Code Chapter 4729. Patients should verify that their compounding pharmacy holds a current Ohio Terminal Distributor of Dangerous Drugs license and compounds under USP <795> standards. The FDA's guidance on pharmacy compounding emphasizes that compounded drugs are not FDA-approved and do not undergo the same safety and efficacy review as branded products.

Telehealth Prescribing of Jatenzo in Ohio

Ohio law permits telehealth prescribing of Jatenzo. The Ohio Medical Board's telemedicine rules allow prescribers to establish a physician-patient relationship via synchronous audio-video encounters, after which Schedule III controlled substances like testosterone can be prescribed. Ohio codified expanded telehealth access following emergency provisions adopted during the COVID-19 pandemic.

Telehealth platforms operating in Ohio must use prescribers licensed by the State Medical Board of Ohio. A Telehealth and Medicine Today review (2021) found that telehealth-based TRT management produced equivalent patient satisfaction and adherence outcomes compared to in-person care, with 94% of patients reporting high satisfaction scores. Men in rural Ohio counties (Appalachian region, southeast Ohio) benefit most from this access pathway, given the documented shortage of endocrinologists in non-metropolitan areas.

Before starting Jatenzo via telehealth, Ohio patients need baseline labs including total testosterone (two morning draws), complete blood count, PSA (for men over 40), hepatic function panel, and lipid profile. The Endocrine Society guideline specifies these monitoring requirements regardless of the prescribing modality. Follow-up labs are recommended at 3, 6, and 12 months after initiation, then annually.

Jatenzo vs. Other TRT Formulations: Ohio Cost Comparison

A cost comparison helps contextualize Jatenzo's $900 per month price point against alternatives available in Ohio. Generic testosterone cypionate injections cost $30 to $75 per month at Ohio pharmacies. Topical testosterone gel (generic AndroGel) runs $90 to $200 per month. Testosterone nasal gel (Natesto) costs $600 to $800 per month. The testosterone pellet (Testopel) implant procedure costs $500 to $1,200 per insertion every 3 to 6 months.

Jatenzo's oral route of administration avoids transference risk associated with topical gels, a safety concern highlighted in the FDA's boxed warning for topical testosterone. This risk is particularly relevant for men living with children or female partners. The TRAVERSE cardiovascular safety trial (N=5,246) provided reassuring data on testosterone replacement and major adverse cardiovascular events, though it studied topical gel rather than oral TU specifically.

A 2022 cost-effectiveness analysis in the Journal of Urology found that oral testosterone undecanoate's cost per quality-adjusted life year (QALY) was comparable to topical formulations when accounting for adherence advantages and lower discontinuation rates. Men who previously discontinued injectable TRT due to injection site reactions or needle aversion may find the adherence benefit offsets the higher monthly cost.

"For patients who struggle with adherence to injectable regimens, an oral option can meaningfully improve long-term testosterone optimization," notes the Endocrine Society's 2018 guideline panel.

Cardiovascular Monitoring and Safety Considerations

The FDA required a cardiovascular risk evaluation for Jatenzo's label, noting potential increases in blood pressure during clinical trials. Systolic blood pressure increased by a mean of 3 to 5 mmHg in the Swerdloff registration study, a finding that requires clinical context. The label advises blood pressure monitoring before and during treatment.

The TRAVERSE trial, published in the New England Journal of Medicine in 2023, enrolled 5,246 men aged 45 to 80 with hypogonadism and established cardiovascular disease or elevated cardiovascular risk. The primary composite endpoint (death from cardiovascular causes, nonfatal MI, nonfatal stroke) showed a hazard ratio of 0.96 (95% CI, 0.78 to 1.17), indicating no excess cardiovascular risk with testosterone replacement over a mean follow-up of 33 months.

Ohio clinicians should monitor hematocrit at baseline and at 3 to 6 month intervals, as polycythemia remains the most common adverse effect of TRT regardless of formulation. A meta-analysis in Medicine (2020) reported polycythemia rates of 1.6% to 18% across testosterone formulations. The oral route may confer a modest advantage here: the Jatenzo prescribing information reported hematocrit elevations above 54% in 3.2% of treated patients, lower than some injectable formulations.

Dose Titration and Cost Implications

Jatenzo uses a weight-based and response-based titration schedule. The starting dose is 237 mg twice daily, taken with food. After approximately 1 month, clinicians check the average testosterone concentration and adjust to 158 mg twice daily (for levels above range) or 396 mg twice daily (for levels below range). The FDA label specifies taking Jatenzo with meals containing at least 15 grams of fat, as food intake significantly enhances absorption.

"In our trial, patients who consistently took oral TU with a fat-containing meal achieved substantially higher and more consistent serum testosterone levels," reported Swerdloff et al. in the Journal of Clinical Endocrinology & Metabolism.

Dose titration matters for cost. The monthly price remains approximately $900 regardless of dose, since each strength is packaged in comparable 30-day supply quantities. Patients titrated down to 158 mg may have leftover capsules, which does not reduce the per-fill cost but does extend the effective supply. Patients requiring the maximum 396 mg twice-daily dose should confirm their prescription reflects the correct capsule count to avoid mid-month shortfalls.